ResearcherSun Yat-sen UniversityActive in the last 2 years
Jing Chen
Matched on ORCID iD 0000-0003-1532-3550; OpenAlex author ID A5100394965. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2014: 1 paper · 2015: 3 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 7
- SIK1 promotes ferroptosis resistance in pancreatic cancer via HDAC5-STAT6-SLC7A11 axis. Co-author DOI 10.1016/j.canlet.2025.217726↗
- The m7G Reader NCBP2 Promotes Pancreatic Cancer Progression by Upregulating MAPK/ERK Signaling. Co-author DOI 10.3390/cancers15225454↗
- KIF20B Promotes Cell Proliferation and May Be a Potential Therapeutic Target in Pancreatic Cancer. Co-author DOI 10.1155/2021/5572402↗
- Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2014.12.028↗
- LASP1 is a HIF1α target gene critical for metastasis of pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-2040↗
- SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression. Co-author DOI 10.1371/journal.pone.0121338↗
- Hypoxia inducible factor (HIF)-1α directly activates leptin receptor (Ob-R) in pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2014.08.001↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jiancong Xie · 2 shared papers, 2023–2025 · strength 0.36
- Tuo Hu · 2 shared papers, 2023–2025 · strength 0.36
- Weidong Pan · 2 shared papers, 2023–2025 · strength 0.36
- Tao Ma · 1 shared paper, 2025 · strength 0.19
- Hao Zhang · 1 shared paper, 2025 · strength 0.19
- Jihui Hao · 4 shared papers, 2014–2015 · strength 0.18
- Paper Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment… DOI 10.1016/j.biomaterials.2014.12.028↗
- Paper SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression. DOI 10.1371/journal.pone.0121338↗
- Paper Hypoxia inducible factor (HIF)-1α directly activates leptin receptor (Ob-R) in pancreatic cancer cells. DOI 10.1016/j.canlet.2014.08.001↗
- He Ren · 4 shared papers, 2014–2015 · strength 0.18
- Paper Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment… DOI 10.1016/j.biomaterials.2014.12.028↗
- Paper SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression. DOI 10.1371/journal.pone.0121338↗
- Paper Hypoxia inducible factor (HIF)-1α directly activates leptin receptor (Ob-R) in pancreatic cancer cells. DOI 10.1016/j.canlet.2014.08.001↗
- Hao Zhang · 1 shared paper, 2023 · strength 0.17
- Tao Ma · 1 shared paper, 2023 · strength 0.17
- Tao Jiang · 1 shared paper, 2021 · strength 0.16
- Tiansuo Zhao · 3 shared papers, 2014–2015 · strength 0.13
- Paper SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression. DOI 10.1371/journal.pone.0121338↗
- Paper Hypoxia inducible factor (HIF)-1α directly activates leptin receptor (Ob-R) in pancreatic cancer cells. DOI 10.1016/j.canlet.2014.08.001↗
- Paper LASP1 is a HIF1α target gene critical for metastasis of pancreatic cancer. DOI 10.1158/0008-5472.can-14-2040↗
- Xiao Ling Zhao · 2 shared papers, 2015 · strength 0.10
- Huan Zhang · 2 shared papers, 2014–2015 · strength 0.08
- Xiuchao Wang · 2 shared papers, 2015 · strength 0.08
- Yiye Li · 1 shared paper, 2015 · strength 0.05
- Hai Wang · 1 shared paper, 2015 · strength 0.05
- Guangjun Nie · 1 shared paper, 2015 · strength 0.05
- Mingxiao Lang · 1 shared paper, 2015 · strength 0.04
- Ming Yu · 1 shared paper, 2014 · strength 0.04
- Chuntao Gao · 1 shared paper, 2015 · strength 0.04
- Chongbiao Huang · 1 shared paper, 2015 · strength 0.04
- Song Gao · 1 shared paper, 2015 · strength 0.04
- Junwei Sun · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.